Concepts (104)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Patellar Ligament | 2 | 2025 | 12 | 1.900 |
Why?
|
| Tibial Fractures | 2 | 2025 | 59 | 1.800 |
Why?
|
| Reoperation | 1 | 2025 | 819 | 0.760 |
Why?
|
| Osteoporosis | 1 | 2022 | 116 | 0.730 |
Why?
|
| Bone Density | 1 | 2022 | 313 | 0.670 |
Why?
|
| Psoas Muscles | 1 | 2019 | 5 | 0.640 |
Why?
|
| Pelvic Bones | 1 | 2019 | 27 | 0.630 |
Why?
|
| Sarcopenia | 1 | 2019 | 39 | 0.610 |
Why?
|
| Fractures, Bone | 1 | 2019 | 187 | 0.540 |
Why?
|
| Tendon Injuries | 2 | 2025 | 21 | 0.470 |
Why?
|
| Postoperative Complications | 1 | 2025 | 3016 | 0.410 |
Why?
|
| Retrospective Studies | 5 | 2025 | 16039 | 0.250 |
Why?
|
| Radiography | 2 | 2024 | 822 | 0.240 |
Why?
|
| Return to Sport | 1 | 2025 | 5 | 0.240 |
Why?
|
| Weight-Bearing | 1 | 2025 | 45 | 0.240 |
Why?
|
| Range of Motion, Articular | 1 | 2025 | 73 | 0.240 |
Why?
|
| Rotation | 1 | 2024 | 51 | 0.240 |
Why?
|
| Fracture Fixation, Internal | 1 | 2025 | 72 | 0.230 |
Why?
|
| Casts, Surgical | 1 | 2024 | 18 | 0.220 |
Why?
|
| Humeral Fractures | 1 | 2024 | 22 | 0.220 |
Why?
|
| Absorptiometry, Photon | 1 | 2022 | 178 | 0.190 |
Why?
|
| Benzodioxoles | 2 | 2012 | 7 | 0.190 |
Why?
|
| Lumbar Vertebrae | 1 | 2022 | 108 | 0.190 |
Why?
|
| Colorectal Neoplasms | 3 | 2012 | 561 | 0.190 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 452 | 0.180 |
Why?
|
| Quinazolines | 2 | 2012 | 176 | 0.170 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 2826 | 0.160 |
Why?
|
| Male | 6 | 2025 | 60081 | 0.150 |
Why?
|
| Blood-Brain Barrier | 2 | 2009 | 141 | 0.150 |
Why?
|
| Risk Factors | 2 | 2024 | 10016 | 0.150 |
Why?
|
| Female | 6 | 2025 | 65528 | 0.140 |
Why?
|
| Child | 4 | 2025 | 24226 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2012 | 714 | 0.140 |
Why?
|
| Adolescent | 2 | 2025 | 19096 | 0.130 |
Why?
|
| Sex Factors | 1 | 2019 | 1261 | 0.120 |
Why?
|
| Humans | 10 | 2025 | 123072 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 2055 | 0.110 |
Why?
|
| Survival Rate | 1 | 2019 | 1997 | 0.110 |
Why?
|
| Age Factors | 1 | 2019 | 2803 | 0.100 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2012 | 40 | 0.100 |
Why?
|
| Receptor, Notch1 | 1 | 2012 | 65 | 0.100 |
Why?
|
| Camptothecin | 1 | 2012 | 76 | 0.100 |
Why?
|
| 3' Untranslated Regions | 1 | 2012 | 165 | 0.100 |
Why?
|
| Hospitalization | 1 | 2019 | 1728 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 340 | 0.090 |
Why?
|
| CD59 Antigens | 1 | 2009 | 2 | 0.080 |
Why?
|
| Pituitary Diseases | 1 | 2009 | 10 | 0.080 |
Why?
|
| Complement C5a | 1 | 2009 | 23 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2025 | 12123 | 0.080 |
Why?
|
| Brain Edema | 1 | 2009 | 69 | 0.080 |
Why?
|
| Burns | 1 | 2009 | 77 | 0.080 |
Why?
|
| Encephalitis | 1 | 2009 | 109 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 6371 | 0.070 |
Why?
|
| Sepsis | 1 | 2009 | 477 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2012 | 887 | 0.060 |
Why?
|
| Brain Injuries | 1 | 2009 | 762 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 1660 | 0.050 |
Why?
|
| Aged | 1 | 2019 | 19094 | 0.050 |
Why?
|
| Immunoblotting | 2 | 2012 | 312 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 238 | 0.050 |
Why?
|
| Gene Dosage | 2 | 2012 | 440 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2012 | 757 | 0.040 |
Why?
|
| Mutation | 1 | 2012 | 5764 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2012 | 1012 | 0.040 |
Why?
|
| Brain | 1 | 2009 | 2962 | 0.030 |
Why?
|
| Pediatrics | 1 | 2024 | 1141 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2012 | 3293 | 0.030 |
Why?
|
| Mice | 4 | 2012 | 17538 | 0.030 |
Why?
|
| Biomarkers, Tumor | 2 | 2012 | 1439 | 0.030 |
Why?
|
| Apoptosis | 2 | 2010 | 1782 | 0.030 |
Why?
|
| Animals | 5 | 2012 | 33791 | 0.030 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2012 | 62 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2012 | 74 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 198 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2012 | 90 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2012 | 694 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2012 | 269 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2012 | 4490 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 231 | 0.020 |
Why?
|
| Receptor, Anaphylatoxin C5a | 1 | 2009 | 12 | 0.020 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2009 | 7 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2009 | 33 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2009 | 29 | 0.020 |
Why?
|
| fas Receptor | 1 | 2009 | 41 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2009 | 69 | 0.020 |
Why?
|
| Demyelinating Diseases | 1 | 2009 | 67 | 0.020 |
Why?
|
| Infant | 1 | 2024 | 12355 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2009 | 171 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2024 | 13881 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 803 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 1688 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 523 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2009 | 769 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1214 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2012 | 827 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 1679 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2010 | 2307 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2009 | 2809 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 3654 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2009 | 3719 | 0.010 |
Why?
|
| Biomarkers | 1 | 2009 | 2944 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2009 | 4352 | 0.010 |
Why?
|
| Neurons | 1 | 2009 | 1935 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 4286 | 0.010 |
Why?
|